KE3357A - Pyridopyrimidines - Google Patents

Pyridopyrimidines

Info

Publication number
KE3357A
KE3357A KE3357A KE335783A KE3357A KE 3357 A KE3357 A KE 3357A KE 3357 A KE3357 A KE 3357A KE 335783 A KE335783 A KE 335783A KE 3357 A KE3357 A KE 3357A
Authority
KE
Kenya
Prior art keywords
pyridopyrimidines
Prior art date
Application number
KE3357A
Other languages
English (en)
Inventor
Frederick Juby Peter
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of KE3357A publication Critical patent/KE3357A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40Acylated substituent nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
KE3357A 1977-05-25 1983-12-15 Pyridopyrimidines KE3357A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/800,264 US4122274A (en) 1977-05-25 1977-05-25 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones

Publications (1)

Publication Number Publication Date
KE3357A true KE3357A (en) 1984-02-03

Family

ID=25177928

Family Applications (1)

Application Number Title Priority Date Filing Date
KE3357A KE3357A (en) 1977-05-25 1983-12-15 Pyridopyrimidines

Country Status (26)

Country Link
US (1) US4122274A (enExample)
JP (1) JPS6050197B2 (enExample)
AT (1) AT365187B (enExample)
AU (1) AU521211B2 (enExample)
BE (1) BE867295A (enExample)
CA (1) CA1098520A (enExample)
CH (1) CH642656A5 (enExample)
CY (1) CY1218A (enExample)
DE (1) DE2822544A1 (enExample)
DK (1) DK160279C (enExample)
FI (1) FI64594C (enExample)
FR (1) FR2401159A1 (enExample)
GB (1) GB1596476A (enExample)
GR (1) GR71887B (enExample)
HK (1) HK25884A (enExample)
IE (1) IE46849B1 (enExample)
IT (1) IT1105040B (enExample)
KE (1) KE3357A (enExample)
LU (1) LU79694A1 (enExample)
MY (1) MY8500305A (enExample)
NL (1) NL190702C (enExample)
NO (1) NO150361C (enExample)
SE (1) SE437830B (enExample)
SG (1) SG73383G (enExample)
YU (2) YU42163B (enExample)
ZA (1) ZA782816B (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4495189A (en) * 1975-11-27 1985-01-22 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara R.T. Condensed pyrimidines
HU173438B (hu) * 1975-11-27 1979-05-28 Chinoin Gyogyszer Es Vegyeszet Sposob poluchenija novykh proizvodnykh 4-okso-1,6,7,8-/tetragidro-4h-pirido/1,2/pirimidina s zaderzhivajuhhejj vozgoranie aktivnot'ju i protivosvertivajuhhem effektom
HU180439B (en) * 1977-12-29 1983-03-28 Chinoin Gyogyszer Es Vegyeszet Process for producing 9-amino-pyrido-square bracket-1,2-a-square bracket closed-pyrimidine derivatives
US4192944A (en) * 1978-04-03 1980-03-11 Bristol-Myers Company Optionally substituted 4-oxo-4H-pyrido[1,2-a]pyrimidine-3-N-(1H-tetrazol-4-yl)carboxamides and their use as antiallergy agents
US4223031A (en) * 1978-05-05 1980-09-16 Mead Johnson & Company Azolopyrimidinones
US4491587A (en) * 1978-05-05 1985-01-01 Mead Johnson & Company Tetrazole derivatives
US4282360A (en) * 1979-10-12 1981-08-04 Hoffmann-La Roche Inc. 7-Methylthio or methylsulfinyl-5-oxo-5H-thiazolo[2,3-b]quinazoline-2-carboxylic acid
US4419357A (en) * 1982-01-18 1983-12-06 The Dow Chemical Company 3-(1H-Tetrazol-5-yl)-4(3H)-quinazolinones
US4507477A (en) * 1982-09-09 1985-03-26 Riker Laboratories, Inc. Process for tetrazolyl-pyrimidinone derivatives
US4474953A (en) * 1982-09-09 1984-10-02 Riker Laboratories, Inc. Process and intermediates for the preparation of 3(1H-tetrazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-ones
US4476130A (en) * 1982-09-09 1984-10-09 Riker Laboratories, Inc. 3-(1H-Tetrazol-5-yl)-4H-pyrimido[2,1-b]benzoxazol-4-one compounds exhibiting anti-allergic activity
US4457932A (en) * 1983-07-22 1984-07-03 Bristol-Myers Company Anti-ulcer agents
CA1283411C (en) * 1985-09-25 1991-04-23 Masami Doteuchi 9-(substituted thio)-4h-pyrido[1,2-a]-pyrimidin-4-one derivatives
JPS63183581A (ja) * 1985-10-03 1988-07-28 Tokyo Tanabe Co Ltd ピリド〔1,2−a〕ピリミジン誘導体、その製造法及びそれを有効成分とするアレルギ−疾患治療薬
JPS62242682A (ja) * 1986-04-16 1987-10-23 Tokyo Tanabe Co Ltd 新規なピリド[1,2―a]ピリミジン誘導体及びその製造法
JP2504788B2 (ja) * 1987-11-10 1996-06-05 東京田辺製薬株式会社 9−メチル−3−(1H−テトラゾ―ル−5−イル)−4H−ピリド[1,2−a]ピリミジン−4−オンカリウム塩の水性製剤
US5034230A (en) * 1987-12-25 1991-07-23 Santen Pharmaceutical Co., Ltd. Anti-allergic ophthalmics
CA2010336C (en) * 1989-02-27 1996-11-19 Atsunori Sano Process for producing pyrido[1,2-a]pyrimidine derivative
HU209793B (en) * 1990-09-25 1994-11-28 Chinoin Gyogyszer Es Vegyeszet Process for the production of pyrido[1,2-a]pyrimidine-derivatives and pharmaceutical compositions containing the same
EP0653209A4 (en) 1992-07-30 1997-03-19 Tokyo Tanabe Co Remedy for inflammatory intestinal diseases.
US5527802A (en) * 1992-10-01 1996-06-18 Bristol-Myers Squibb Company New uses of 3-tetrazolo -5,6,7,8- substituted-pyrido (1,2-a) pyrimidin-4-ones
JPH0892093A (ja) * 1994-11-10 1996-04-09 Tokyo Tanabe Co Ltd 9−メチル−3−(1H−テトラゾール−5−イル)−4H−ピリド[1,2−a]ピリミジン−4−オンの水性製剤
WO2002072580A1 (en) * 2001-02-26 2002-09-19 Mitsubishi Pharma Corporation Preventives and/or remedies for kidney diseases and kidney failure
ITMI20011764A1 (it) 2001-08-10 2003-02-10 Dinamite Dipharma Spa Metodo per l'ottenimento del pemirolast ad elevata purezza
GB0316546D0 (en) * 2003-07-15 2003-08-20 Novartis Ag Process for the manufacture of organic compounds
AU2007336118A1 (en) * 2006-12-18 2008-06-26 Cardoz Ab New combination for use in the treatment of inflammatory disorders
WO2008075028A1 (en) * 2006-12-20 2008-06-26 Cardoz Ab New combination for use in the treatment of inflammatory disorders
WO2009007675A2 (en) * 2007-07-11 2009-01-15 Cardoz Ab Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a p2 gamma 12 antagonist
CA2693628A1 (en) * 2007-07-11 2009-01-15 Cardoz Ab New combination for use in the treatment of imflammatory disorders
WO2009007679A2 (en) * 2007-07-11 2009-01-15 Cardoz Ab Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a thromboxane a2 antagonist
US20110092463A1 (en) * 2008-04-07 2011-04-21 Johan Raud Combination for use in the treatment of inflammatory disorders
NZ596747A (en) * 2009-06-16 2014-01-31 Cardoz Ab Crystalline form of pemirolast
USD661900S1 (en) 2010-02-22 2012-06-19 Bajer Design & Marketing, Inc. Collapsible structure
DK2812004T3 (en) * 2012-02-10 2018-10-15 Ptc Therapeutics Inc COMPOUNDS FOR TREATMENT OF SPINAL MUSCLE DROPHY
CN104302181B (zh) 2012-03-01 2017-09-15 Ptc医疗公司 用于治疗脊髓性肌萎缩的化合物
KR102109992B1 (ko) 2012-03-23 2020-05-13 피티씨 테라퓨틱스, 인크. 척수성 근위축증을 치료하기 위한 화합물
EP3082820B1 (en) 2013-12-19 2022-07-20 PTC Therapeutics, Inc. Methods for modulating the amount of rna transcripts
US20160243122A1 (en) 2014-10-23 2016-08-25 Rspr Pharma Ab Use of pemirolast in the treatment of acute asthma
WO2016102941A1 (en) 2014-12-22 2016-06-30 Rspr Pharma Ab New combination of pemirolast and montelukast
EP3298017B1 (en) * 2015-05-20 2019-08-14 H. Hoffnabb-La Roche Ag Compounds for treating spinal muscular atrophy
EP4249472A3 (en) 2015-05-30 2023-12-13 PTC Therapeutics, Inc. Methods for modulating rna splicing
GB201518831D0 (en) 2015-10-23 2015-12-09 Rspr Pharma Ab New use
IL294124B2 (en) 2015-12-10 2024-02-01 Ptc Therapeutics Inc Methods for treating huntington's disease
GB201601138D0 (en) * 2016-01-21 2016-03-09 Rspr Pharma Ab New use
EA201991309A1 (ru) 2016-11-28 2019-11-29 Способы модуляции сплайсинга рнк
US11407753B2 (en) 2017-06-05 2022-08-09 Ptc Therapeutics, Inc. Compounds for treating Huntington's disease
KR20200017476A (ko) 2017-06-14 2020-02-18 피티씨 테라퓨틱스, 인크. Rna 스플라이싱의 변경 방법
US11382918B2 (en) 2017-06-28 2022-07-12 Ptc Therapeutics, Inc. Methods for treating Huntington's Disease
WO2019005993A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. METHODS OF TREATING HUNTINGTON'S DISEASE
MX2020009957A (es) 2018-03-27 2021-01-15 Ptc Therapeutics Inc Compuestos para el tratamiento de enfermedad de hungtinton.
EP3814345B8 (en) 2018-06-27 2024-10-30 PTC Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
PL3814357T3 (pl) 2018-06-27 2024-09-16 Ptc Therapeutics, Inc. Związki heterocykliczne i heteroarylowe do leczenia choroby huntingtona
EP3814360B8 (en) 2018-06-27 2024-11-06 PTC Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
WO2020231977A1 (en) 2019-05-13 2020-11-19 Ptc Therapeutics, Inc. Compounds for treating huntington's disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3072485A (en) * 1960-08-24 1963-01-08 Eastman Kodak Co Optically sensitized azido polymers for photomechanical resist compositions
DE1670480C2 (de) * 1966-11-02 1983-06-01 Chinoin Gyógyszer és Vegyészeti Termékek Gyára R.T., 1045 Budapest Pyrido[1,2-a]pyrimidinderivate, Verfahren zu deren Herstellung sowie diese Verbindungen enthaltende pharmazeutische Präparate
US3960847A (en) * 1972-04-17 1976-06-01 E. R. Squibb & Sons, Inc. 9-Substituted-4-oxopyrido(1,2-α)pyrimidine-3-carboxylic acids and derivatives thereof
US3929787A (en) * 1974-04-22 1975-12-30 Squibb & Sons Inc 6,7,8,9-Tetrahydro-pyrido(1,2-a)pyrimidin-4-ones
US3960863A (en) * 1974-06-25 1976-06-01 Sankyo Company Limited Pyrido[1,2-a]pyrimidinone derivatives
US4017625A (en) * 1975-08-01 1977-04-12 Pfizer Inc. Anti-allergic N-(5-tetrazolyl)-1-oxo-1H-6-alkoxypyrimido-[1,2-a]quinoline-2-carboxamides and intermediates therefor
US4012387A (en) * 1975-09-18 1977-03-15 Warner-Lambert Company Benzo-[g]pyrido[2,1-b]quinazolinones

Also Published As

Publication number Publication date
LU79694A1 (fr) 1979-02-02
AT365187B (de) 1981-12-28
FI64594B (fi) 1983-08-31
IE781036L (en) 1978-11-25
MY8500305A (en) 1985-12-31
CA1098520A (en) 1981-03-31
CY1218A (en) 1984-04-06
YU42163B (en) 1988-06-30
YU123678A (en) 1983-02-28
YU44212B (en) 1990-04-30
DK160279B (da) 1991-02-18
US4122274A (en) 1978-10-24
ZA782816B (en) 1979-05-30
IT1105040B (it) 1985-10-28
SG73383G (en) 1984-08-03
HK25884A (en) 1984-03-30
SE7805954L (sv) 1978-11-26
CH642656A5 (de) 1984-04-30
IE46849B1 (en) 1983-10-05
NO150361C (no) 1984-10-03
ATA373278A (de) 1981-05-15
YU233082A (en) 1988-08-31
NO150361B (no) 1984-06-25
JPS5436294A (en) 1979-03-16
DK160279C (da) 1991-07-22
DE2822544A1 (de) 1978-12-07
FI781614A7 (fi) 1978-11-26
GR71887B (enExample) 1983-08-04
FR2401159B1 (enExample) 1983-05-20
JPS6050197B2 (ja) 1985-11-07
IT7849523A0 (it) 1978-05-24
NO781786L (no) 1978-11-28
AU3631978A (en) 1979-11-29
NL190702C (nl) 1994-07-01
FI64594C (fi) 1983-12-12
SE437830B (sv) 1985-03-18
BE867295A (fr) 1978-11-20
GB1596476A (en) 1981-08-26
DK228878A (da) 1978-11-26
DE2822544C2 (enExample) 1988-10-27
FR2401159A1 (fr) 1979-03-23
NL190702B (nl) 1994-02-01
AU521211B2 (en) 1982-03-25
NL7805534A (nl) 1978-11-28

Similar Documents

Publication Publication Date Title
MY8500305A (en) Pyridopyrimidines
GB2010944B (en) Sound-absorbingstructures
JPS545117A (en) Turboofeeder
AU4201478A (en) Step-stools
GB2005266A (en) 4-amino-4-arylcyclohexanols
GB2005799A (en) Airsprings
JPS5459291A (en) Sulphoneamide
HK13681A (en) Pyridobenzodiazepines
GB2005664A (en) 6-deoxyneamines
AU3828478A (en) Benzodiazepine-diones
GB2002751A (en) Imidazo-isoquinoline-diones
GB2005971B (en) Tailers
GB1556977A (en) Psrayer
CS541878A1 (en) Zpusob vyroby tricyklickych derivatu pyrimidinu
GB2009167B (en) Benzoxazolyl-phenyl-stilbenes
GB2003498A (en) Chrome-tanning
AU3533578A (en) Micro-mill-mixer
JPS53116372A (en) Steroidspirooxazolidine
JPS53135031A (en) Fauset
AU3939978A (en) 2-guanidinomethyl-indoline
BG28612A1 (en) Auto- train
IL52121A0 (en) Polyvinylbenzylamine
JPS53105497A (en) Triazoloothienoodiazepinee11one
GB2006766A (en) Ureidonitriles
JPS53102527A (en) Tructor